Squarepoint’s Jazz Pharmaceuticals JAZZ Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $12.8M | Buy |
+53,148
| New | +$11.6M | 0.01% | 944 |
|
|
2026
Q1 | – | Sell |
-23,127
| Closed | -$3.93M | – | 4615 |
|
|
2025
Q4 | $3.93M | Buy |
23,127
+7,310
| +46% | +$1.12M | ﹤0.01% | 1601 |
|
|
2025
Q3 | $2.08M | Buy |
+15,817
| New | +$1.9M | ﹤0.01% | 2068 |
|
|
2025
Q2 | – | Sell |
-58,787
| Closed | -$7.3M | – | 4762 |
|
|
2025
Q1 | $7.3M | Buy |
+58,787
| New | +$7.67M | 0.01% | 1194 |
|
|
2024
Q3 | – | Sell |
-3,674
| Closed | -$392K | – | 4397 |
|
|
2024
Q2 | $392K | Sell |
3,674
-60,531
| -94% | -$6.65M | ﹤0.01% | 3252 |
|
|
2024
Q1 | $7.73M | Sell |
64,205
-51,931
| -45% | -$6.36M | 0.01% | 1157 |
|
|
2023
Q4 | $14.3M | Buy |
116,136
+64,301
| +124% | +$8.02M | 0.03% | 726 |
|
|
2023
Q3 | $6.71M | Sell |
51,835
-9,387
| -15% | -$1.25M | 0.02% | 997 |
|
|
2023
Q2 | $7.59M | Buy |
+61,222
| New | +$8.24M | 0.02% | 823 |
|
|
2022
Q3 | – | Sell |
-10,670
| Closed | -$1.67M | – | 3200 |
|
|
2022
Q2 | $1.67M | Sell |
10,670
-56,856
| -84% | -$8.75M | 0.01% | 1303 |
|
|
2022
Q1 | $10.5M | Sell |
67,526
-15,073
| -18% | -$2.19M | 0.05% | 438 |
|
|
2021
Q4 | $10.5M | Buy |
82,599
+5,585
| +7% | +$734K | 0.03% | 499 |
|
|
2021
Q3 | $10M | Buy |
77,014
+1,308
| +2% | +$198K | 0.03% | 493 |
|
|
2021
Q2 | $13.4M | Sell |
75,706
-3,939
| -5% | -$682K | 0.05% | 356 |
|
|
2021
Q1 | $13.1M | Buy |
+79,645
| New | +$13.1M | 0.08% | 287 |
|
|
2020
Q4 | – | Sell |
-30,225
| Closed | -$4.31M | – | 3095 |
|
|
2020
Q3 | $4.31M | Sell |
30,225
-43,438
| -59% | -$5.39M | 0.06% | 382 |
|
|
2020
Q2 | $8.13M | Buy |
73,663
+67,784
| +1,153% | +$7.5M | 0.13% | 225 |
|
|
2020
Q1 | $586K | Sell |
5,879
-25,648
| -81% | -$3.32M | 0.02% | 956 |
|
|
2019
Q4 | $4.71M | Buy |
31,527
+27,884
| +765% | +$3.79M | 0.03% | 524 |
|
|
2019
Q3 | $467K | Sell |
3,643
-30,557
| -89% | -$4.1M | ﹤0.01% | 1657 |
|
|
2019
Q2 | $4.88M | Buy |
34,200
+14,061
| +70% | +$1.89M | 0.05% | 449 |
|
|
2019
Q1 | $2.88M | Sell |
20,139
-145,619
| -88% | -$19M | 0.03% | 626 |
|
|
2018
Q4 | $20.5M | Buy |
165,758
+89,303
| +117% | +$13.2M | 0.24% | 85 |
|
|
2018
Q3 | $12.9M | Buy |
+76,455
| New | +$13.1M | 0.15% | 175 |
|
|
2018
Q2 | – | Sell |
-2,314
| Closed | -$349K | – | 1890 |
|
|
2018
Q1 | $349K | Sell |
2,314
-7,030
| -75% | -$1.03M | 0.01% | 1245 |
|
|
2017
Q4 | $1.26M | Buy |
+9,344
| New | +$1.3M | 0.02% | 731 |
|
|
2017
Q3 | – | Sell |
-10,765
| Closed | -$1.67M | – | 1740 |
|
|
2017
Q2 | $1.67M | Buy |
+10,765
| New | +$1.65M | 0.03% | 571 |
|
|
2016
Q3 | – | Sell |
-17,000
| Closed | -$2.4M | – | 1129 |
|
|
2016
Q2 | $2.4M | Buy |
+17,000
| New | +$2.51M | 0.15% | 151 |
|
|
2016
Q1 | – | Sell |
-3,700
| Closed | -$520K | – | 1307 |
|
|
2015
Q4 | $520K | Buy |
+3,700
| New | +$513K | 0.06% | 517 |
|
Other funds holding JAZZ
Squarepoint's JAZZ Position: Q2 2026 in Review
Squarepoint opened a new position in Jazz Pharmaceuticals (JAZZ) in Q2 2026: 53,148 shares worth $12.8M. The stake represents 0.01% of the portfolio and ranks #944 among its holdings. This is a return to the name: Squarepoint previously reported a position in JAZZ as recently as Q4 2025.
Squarepoint first reported a position in JAZZ in Q4 2015 and has held it in 29 quarters since. The position peaked at $20.5M in Q4 2018. 646 funds tracked by Wall St. Rank hold JAZZ as of Q2 2026.
- Squarepoint held 53,148 shares of Jazz Pharmaceuticals worth $12.8M as of Q2 2026.
- Jazz Pharmaceuticals was a new Squarepoint position in Q2 2026.
- Jazz Pharmaceuticals made up 0.01% of Squarepoint's portfolio in Q2 2026, its #944 holding.
- Squarepoint first reported a position in Jazz Pharmaceuticals in Q4 2015 and has held it in 29 quarters since.
- Squarepoint's Jazz Pharmaceuticals position peaked at $20.5M in Q4 2018.
- 646 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q2 2026.
Based on Squarepoint's 13F filing for Q2 2026, filed 14 Aug 2026.